Roche to Initiate Screening with the Cobas® Babesia TestOctober 13th, 2017
Hematology Analyzers & Reagents Market to Reach US $4 Billion by 2022October 11th, 2017
MEDICA 2017 - World Forum for Medicine
Düsseldorf, GermanyBooth No.: 3/D35-2
69th AACC Annual Meeting and Clinical Lab Expo - July 30 - August 3, 2017
SAN DIEGO, CA, USA
Thanks to Block Scientific, I was able to procure the re-certified Bayer DCA 2000+ without hassles and get the lab back in operation. The
device works perfectly and I look forward to doing more business with Block Scientific.
--- Mathew Anderson, New Jersey
The DRG Tuberculosis Sensitive ELISA has been designed for the detection and the quantification of specific IgG / IgM / IgA antibodies respectively against Mycobacterium tuberculosis in serum and plasma. Further applications in other body fluids are possible and can be provided on request.
Mycobacterioses (tuberculosis, leprosy, atypical mycobacterioses, paratuberculosis and perhaps Crohn’s Disease) are the infectious diseases of men and animals with the largest diffusion on earth. The infectious agents of tuberculosis are acidresistant rod-like formed bacteria of the family Mycobacteriaceae, genus Mycobacterium. The germ was detected by Robert Koch in 1882. Owing to the very high infectious power of pathogenic mycobacteria, early diagnosis is essential to prevent spreading of the disease.
Convergences of various approaches are necessary to control the mycobacterioses,
immune reactions and bacterial shedding being variable during the diseases. However, usual diagnostic procedures were up to now unsatisfying and did not allow the differentiation of mycobacterial species. The illness is normally transferred by droplets of saliva from infected persons. The target of the infection are mostly the lungs but also other organs like the brain, intestinal tract, bones, lymph nodes and kidneys can be afflicted. Tuberculosis is
not only found in developing countries with 8 million of new infections yearly but also in industrialized civilisations as an actual disease with some thousands of cases yearly. Without treatment the disease leads in 50 % of the cases to death within less than two years. Clinical symptoms are fatigue, loss of weight, lack of appetite, light fever, nocturnal sweat and
pain in the chest. Especially patients with HIV are threatened by tuberculosis due to their impaired immune system.
A vaccination with living attenuated bacteria is possible (BCG = Bacille Calmette Guérin). This is mostly done with newborn or young children. With older patients, before the vaccination there is normally performed the tuberculin test (Pirquet or Mantoux) where a small amount of tuberculin is injected under the skin. In a positive case there exist antibodies against Mycobacteria and a vaccination is not necessary.
Up to recently, there have not existed any serological methods to detect tuberculosis antibodies in serum. The only available procedure was besides the skin tuberculin test the direct microscopical identification of the dyed bacteria in sputum. Meanwhile specific antigens have been prepared either by purification of natural material or by recombinant methods. In the ELISA kits for the determination of IgG / IgM / IgA antibodies purified PPD proteins are used in order to determine an immune response against the bacteria in human serum. A fresh or chronically active infection can be
diagnosed by IgA and IgM tests.